BAJAJ BROKING

Notification close image
No new Notification messages
card image
Travel Food Services IPO is Open!
Apply for the Travel Food Services IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

81

0

BETA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

BETA DRUGS LIMITED performance

Today’s low

Today’s high

₹ 1760.00 ₹ 1793.00
₹ 1793.00

52 week low

52 week high

₹ 1121.90 ₹ 2215.24
₹ 1793.00

Open Price

₹ 1764.80

Prev. Close

₹ 1773.65

Volume (Shares)

630.00

Total traded value

₹ 11.29

Upper Circuit

₹ 2128.35

Lower Circuit

₹ 1418.95

info

BETA DRUGS LIMITED Share Price Update

As of the latest trading session, BETA DRUGS LIMITED share price is currently at ₹ 1793, which is up by ₹ 19.34 from its previous closing. Today, the stock has fluctuated between ₹ 1760.00 and ₹ 1793.00. Over the past year, BETA DRUGS LIMITED has achieved a return of 54.33 %. In the last month alone, the return has been -1.65 %. Read More...

Investment Returns

Over 1 Month -1.65% Over 3 Months -3.60% Over 6 Months -10.30% Over 1 Year 54.33%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

BETA DRUGS LIMITED fundamentals


  • Market cap (Cr)

    1,810.00

  • P/E Ratio (TTM)

    116.00

  • Beta

    1.42

  • Book Value / share

    127.82

  • Return on equity

    20.67%

  • EPS (TTM)

    18.58

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.00

info icon alternate text
  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

info icon alternate text

BETA DRUGS LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 220.20
Operating Expense 200.98
Net Profit 15.43
Net Profit Margin (%) 7.00
Earnings Per Share (EPS) 15.29
EBITDA 33.04
Effective Tax Rate (%) 25.95
Particulars MAR 2024 (Values in Cr)
Revenue 197.62
Operating Expense 169.87
Net Profit 21.94
Net Profit Margin (%) 11.10
Earnings Per Share (EPS) 22.82
EBITDA 35.25
Effective Tax Rate (%) 25.61
Particulars MAR 2023 (Values in Cr)
Revenue 157.87
Operating Expense 133.71
Net Profit 18.82
Net Profit Margin (%) 11.92
Earnings Per Share (EPS) 19.57
EBITDA 32.24
Effective Tax Rate (%) 25.34
Particulars MAR 2022 (Values in Cr)
Revenue 124.85
Operating Expense 105.53
Net Profit 14.25
Net Profit Margin (%) 11.41
Earnings Per Share (EPS) 14.82
EBITDA 26.04
Effective Tax Rate (%) 29.36
Particulars MAR 2021 (Values in Cr)
Revenue 79.46
Operating Expense 70.17
Net Profit 6.98
Net Profit Margin (%) 8.78
Earnings Per Share (EPS) 7.26
EBITDA 15.92
Effective Tax Rate (%) 29.35
Particulars MAR 2024 (Values in Cr)
Book Value / Share 163.43
ROE % 26.03
ROCE % 31.58
Total Debt to Total Equity 0.12
EBITDA Margin 20.75
Particulars MAR 2023 (Values in Cr)
Book Value / Share 127.82
ROE % 28.55
ROCE % 32.63
Total Debt to Total Equity 0.19
EBITDA Margin 23.72
Particulars MAR 2022 (Values in Cr)
Book Value / Share 96.05
ROE % 30.85
ROCE % 34.77
Total Debt to Total Equity 0.24
EBITDA Margin 23.64
Particulars MAR 2021 (Values in Cr)
Book Value / Share 71.37
ROE % 18.64
ROCE % 21.20
Total Debt to Total Equity 0.32
EBITDA Margin 21.74
Particulars MAR 2020 (Values in Cr)
Book Value / Share 59.41
ROE % 19.22
ROCE % 19.97
Total Debt to Total Equity 0.43
EBITDA Margin 20.17
Particulars MAR 2024 (Values in Cr)
Book Value / Share 120.67
ROE % 20.67
ROCE % 26.60
Total Debt to Total Equity 0.05
EBITDA Margin 17.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 100.12
ROE % 21.67
ROCE % 27.20
Total Debt to Total Equity 0.07
EBITDA Margin 20.42
Particulars MAR 2022 (Values in Cr)
Book Value / Share 80.57
ROE % 20.23
ROCE % 26.19
Total Debt to Total Equity 0.09
EBITDA Margin 20.86
Particulars MAR 2021 (Values in Cr)
Book Value / Share 65.96
ROE % 11.65
ROCE % 15.59
Total Debt to Total Equity 0.12
EBITDA Margin 20.04
Particulars MAR 2020 (Values in Cr)
Book Value / Share 58.71
ROE % 14.63
ROCE % 16.64
Total Debt to Total Equity 0.17
EBITDA Margin 18.63
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 28.63
Total Assets 254.09
Total Liabilities 254.09
Total Equity 157.11
Share Outstanding 9613790
Price to Book Ratio 10.22
Return on Assets (%) 14.33
Return on Capital (%) 21.67
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 19.16
Total Assets 198.42
Total Liabilities 198.42
Total Equity 122.88
Share Outstanding 9613790
Price to Book Ratio 6.26
Return on Assets (%) 15.48
Return on Capital (%) 22.11
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 17.32
Total Assets 157.85
Total Liabilities 157.85
Total Equity 92.34
Share Outstanding 9613790
Price to Book Ratio 7.02
Return on Assets (%) 15.72
Return on Capital (%) 22.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 10.42
Total Assets 117.50
Total Liabilities 117.50
Total Equity 68.61
Share Outstanding 9613790
Price to Book Ratio 1.82
Return on Assets (%) 9.97
Return on Capital (%) 14.08
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 5.38
Total Assets 107.17
Total Liabilities 107.17
Total Equity 57.11
Share Outstanding 9613790
Price to Book Ratio 0.68
Return on Assets (%) 8.78
Return on Capital (%) 12.22
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 27.19
Total Assets 170.47
Total Liabilities 170.47
Total Equity 116.01
Share Outstanding 9613790
Price to Book Ratio 10.22
Return on Assets (%) 12.86
Return on Capital (%) 18.34
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 17.79
Total Assets 134.04
Total Liabilities 134.04
Total Equity 96.25
Share Outstanding 9613790
Price to Book Ratio 6.26
Return on Assets (%) 14.03
Return on Capital (%) 18.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 15.58
Total Assets 110.89
Total Liabilities 110.89
Total Equity 77.46
Share Outstanding 9613790
Price to Book Ratio 7.02
Return on Assets (%) 12.84
Return on Capital (%) 17.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 8.26
Total Assets 86.23
Total Liabilities 86.23
Total Equity 63.41
Share Outstanding 9613790
Price to Book Ratio 1.82
Return on Assets (%) 8.09
Return on Capital (%) 10.37
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 4.16
Total Assets 82.21
Total Liabilities 82.21
Total Equity 56.43
Share Outstanding 9613790
Price to Book Ratio 0.68
Return on Assets (%) 8.63
Return on Capital (%) 11.12
Particulars MAR 2024 (Values in Cr)
Net Income 48.75
Cash from Operations 30.93
Cash from Investing -13.97
Cash from Financing -7.48
Net change in Cash 9.46
Free Cash Flow 42.54
Particulars MAR 2023 (Values in Cr)
Net Income 41.05
Cash from Operations 23.38
Cash from Investing -19.06
Cash from Financing -2.47
Net change in Cash 1.83
Free Cash Flow 41.59
Particulars MAR 2022 (Values in Cr)
Net Income 34.30
Cash from Operations 29.62
Cash from Investing -21.75
Cash from Financing -0.97
Net change in Cash 6.89
Free Cash Flow 49.05
Particulars MAR 2021 (Values in Cr)
Net Income 15.95
Cash from Operations 18.59
Cash from Investing -5.84
Cash from Financing -7.71
Net change in Cash 5.03
Free Cash Flow 24.35
Particulars MAR 2020 (Values in Cr)
Net Income 11.97
Cash from Operations 8.41
Cash from Investing -15.05
Cash from Financing 8.72
Net change in Cash 2.08
Free Cash Flow 23.71
Particulars MAR 2024 (Values in Cr)
Net Income 29.48
Cash from Operations 21.18
Cash from Investing -11.02
Cash from Financing -0.76
Net change in Cash 9.40
Free Cash Flow 27.62
Particulars MAR 2023 (Values in Cr)
Net Income 25.20
Cash from Operations 10.22
Cash from Investing -5.81
Cash from Financing -2.19
Net change in Cash 2.21
Free Cash Flow 17.13
Particulars MAR 2022 (Values in Cr)
Net Income 20.16
Cash from Operations 18.76
Cash from Investing -12.71
Cash from Financing 1.26
Net change in Cash 7.31
Free Cash Flow 28.37
Particulars MAR 2021 (Values in Cr)
Net Income 9.88
Cash from Operations 11.59
Cash from Investing -3.15
Cash from Financing -4.34
Net change in Cash 4.10
Free Cash Flow 15.03
Particulars MAR 2020 (Values in Cr)
Net Income 8.95
Cash from Operations 6.09
Cash from Investing -14.32
Cash from Financing 9.47
Net change in Cash 1.24
Free Cash Flow 13.60
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.37 32.19 1.99 278.72 34.11 / 77.70
BLISS GVS PHARMA LTD 161.00 20.15 1.61 1697.67 105.05 / 184.95
CIPLA LTD 1488.15 23.36 3.85 120199.04 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 339.30 12.99 2.75 998.59 189.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.37 93.26 5.74 278.72 34.11 / 77.70
AMRUTAJAN HEALTH LTD 709.65 40.37 6.28 2051.64 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 9136.70 130.49 29.65 22841.75 6222.35 / 10653.05
BLISS GVS PHARMA LTD 161.00 24.62 1.60 1697.67 105.05 / 184.95

BETA DRUGS LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1793.00 1.09 redarrow
red-green-graph indicator
3 Bearish
13 Bullish
  • 5 Days 1772.30
  • 26 Days 1785.50
  • 10 Days 1771.90
  • 50 Days 1793.90
  • 12 Days 1773.40
  • 100 Days 1789.60
  • 20 Days 1780.90
  • 200 Days 1727.80
1773.38 PIVOT

First Support

1761.77

First Resistance

1785.27

Second Support

1749.88

Second Resistance

1796.88

Third Support

1738.27

Third Resistance

1808.77

RSI

47.91

ADX

29.59

MACD

-12.13

Williams % R

-45.76

Commodity Channel Index (CCI)

-29.71

Date

2025-07-08

Week

3133.00

Same Day

1575.00

Month

2945.00

1 Year

1.43

3 Year

0.76

Over 1 Month

-1.65%

down

Over 1 Year

54.33%

down

Over 3 Months

-3.60%

down

Over 3 Years

40.71%

down

Over 6 Months

-10.30%

down

Over 5 Years

97.51%

down

BETA DRUGS LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
32.36%
Promoter Holdings
66.73%
FII
0.9%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Neeraj Batra 6658746.0 (65.96%) Shareholding of Promoter and Promoter Group
Suryavanshi Commotrade Private Limited 680026.0 (6.74%) Public Shareholding
Ashish Kacholia 583800.0 (5.78%) Public Shareholding
Bsas Infotech Limited 128520.0 (1.27%) Public Shareholding
Onkar Singh 107205.0 (1.06%) Public Shareholding
Rahul Batra 41632.0 (0.41%) Shareholding of Promoter and Promoter Group
Varun Batra 34891.0 (0.35%) Shareholding of Promoter and Promoter Group
Heena Batra 619.0 (0.01%) Shareholding of Promoter and Promoter Group
Aditi Batra 619.0 (0.01%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

BETA DRUGS LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

BETA DRUGS LIMITED Share Price

Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017

Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.

The company is primarily engaged in the manufacturing of oncology products. The Company's products range from anti-cancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease.

The Company set up the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new 'state of the art' manufacturing facility for oncology formulations in 2014; developed in-house Albumin bound Paclitaxel in 2015; started in-house API Plant - Adley Labs in 2017.

In October, 2017, the Company came up with a Public Issue of 22,96,000 Equity Shares by raising equity capital aggregating Rs 19.5 Crores.

The Company set up an Oncology Plant in Uzbekistan in 2018. In 2020, the Company launched GEM-RTU, ADLEAP, ADLANTE, BEXINIB; launched 1st Indian Brand of Dasatinib, BEEDAN. In 2021, the Company launched 1st Indian brand of Sunitinib, ADSUNIB.

Parent organization Indian Private
NSE symbol BETA
Founded 2005
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Beta Drugs Ltd?

Answer Field

Beta Drugs Ltd share price is for NSE ₹ 1,793.00 & for BSE ₹ 0.00 as on Jul 09 2025 11:29 AM.

What is the Market Cap of Beta Drugs Ltd Share?

Answer Field

The market cap of Beta Drugs Ltd for NSE ₹ 1,723.75 & for BSE ₹ 0.00 as on Jul 09 2025 11:29 AM.

What is the 52 Week High and Low of Beta Drugs Ltd?

Answer Field

The 52 Week High and Low of Beta Drugs Ltd for NSE is ₹ 2,215.24 and ₹ 1,121.90 and for BSE is ₹ 0.00 and ₹ 0.00.

What is 1 year return for Beta Drugs Ltd?

Answer Field

The 1 year returns on the stock has been 54.33%.

What is the P/E Ratio of Beta Drugs Ltd Share?

Answer Field

As on Jul 09 2025 11:29 AM the price-to-earnings (PE) ratio for Beta Drugs Ltd share is 116.00.

What is the PB ratio of Beta Drugs Ltd Share?

Answer Field

As on Jul 09 2025 11:29 AM, the price-to-book (PB) ratio for Beta Drugs Ltd share is 127.82.

How to Buy Beta Drugs Ltd Share?

Answer Field

You can trade in Beta Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Beta Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Beta Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Beta Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|